BC Extra | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

Beam expands base editing platform with prime editing  Beam Therapeutics disclosed single base transitions and sickle cell disease as the first applications of its sublicense to prime editing technology from newco Prime Medicine. With the...
BC Innovations | Apr 28, 2016
Finance

Virtually biotechs

Harvard University 's $20 million licensing deal with Merck & Co. Inc in March for a preclinical cancer therapy brought in more cash in one swoop than the university's tech transfer office saw in all...
BC Extra | Mar 22, 2016
Company News

Merck licenses small molecules from Harvard

Merck & Co. Inc. (NYSE:MRK) is paying Harvard University $20 million up front in exchange for an exclusive, worldwide license to preclinical small molecule inhibitors of enzymes that regulate transcription to treat acute myelogenous leukemia...
BC Innovations | Nov 12, 2015
Distillery Techniques

Techniques: Tool compounds for probing cyclin dependent kinase 8 (CDK8)- and cyclin dependent kinase 19 (CDK19; CDC2L6)-dependent tumor growth

CDK8 CDK19 cyclin dependent kinase 8 cyclin dependent kinase 19 CDC2L6 Cardiff University Merck Serono S.A. Merck KGaA The Institute of Cancer Research...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 8 (CDK8); cyclin C (CCNC)

Cancer INDICATION: Leukemia In vitro, cell culture and mouse studies identified cortistatin A as an inhibitor of the CDK8- CCNC interaction that could help treat leukemia. In vitro, cortistatin A bound the CDK8-CCNC complex with...
BC Innovations | Aug 23, 2012
Targets & Mechanisms

CDK8 inhibitor: Senex's best thing

Chemotherapy is used to treat virtually every tumor type, but the drugs can blunt their own efficacy by inducing paracrine activity. Now, an international team led by Senex Biotechnology Inc. has mouse data showing that...
BC Innovations | Aug 16, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin dependent kinase 8 (CDK8); CDK19 (CDC2L6); cyclin-dependent kinase inhibitor 1A (p21, Cip1; CDKN1A; CIP1) In vitro and mouse studies suggest dual CDK8 and...
BC Innovations | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Cyclin-dependent kinase 8 (CDK8); b-catenin A cell-culture and human-tissue study suggests that antagonizing CDK8 could help treat colorectal...
BC Innovations | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer E2F transcription factor 1 (E2F1); cyclin-dependent kinase 8 (CDK8); b-catenin Studies in flies and in human cell culture...
BC Innovations | Sep 25, 2008
Targets & Mechanisms

CDK8 is Enough in Colorectal Cancer

Of the 11 known cyclin-dependent kinases, about half have long been the focus of cancer drug developers because they are involved in controlling cell-cycle progression, which goes into overdrive in cancer. However, none of the...
Items per page:
1 - 10 of 10